Letter to editor: Beyond nimodipine: advanced neuroprotection strategies for aneurysmal subarachnoid hemorrhage vasospasm and delayed cerebral ischemia.
Neurosurg Rev
; 47(1): 383, 2024 Aug 01.
Article
em En
| MEDLINE
| ID: mdl-39085665
ABSTRACT
This critique discusses neuroprotective strategies for aneurysmal subarachnoid hemorrhage (SAH), excluding Nimodipine, emphasizing alternatives like verapamil, albumin, and cilostazol. While these options show potential, their efficacy lacks robust confirmation from randomized controlled trials (RCTs), relying mainly on observational studies and small trials. The letter underscores the need for comprehensive safety assessments and long-term outcome studies to enhance practical application. Highlighting ongoing trials and emerging therapies like clazosentan and TAK-044, it advocates for future research directions focused on large-scale RCTs and combination therapies, such as cilostazol and Nimodipine, which have demonstrated synergistic benefits in reducing delayed cerebral ischemia (DCI) and improving patient outcomes.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Hemorragia Subaracnóidea
/
Nimodipina
/
Isquemia Encefálica
/
Fármacos Neuroprotetores
/
Vasoespasmo Intracraniano
Limite:
Humans
Idioma:
En
Revista:
Neurosurg Rev
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Paquistão